Multivariate prognostic models for OS and EFS in patients with DLBCL
| Outcome . | Model . | Variable . | Hazard ratio . | 95% CI (lower) . | 95% CI (upper) . | P . | Log-rank P . |
|---|---|---|---|---|---|---|---|
| OS | wp-score | wp-score (high)* | Infinite | 0.000 | Infinite | ND | .001 |
| Age | 0.98 | 0.29 | 1.02 | .29 | |||
| Sex (female) | 2.49 | 0.26 | 12.29 | .26 | |||
| EFS | wp-score | wp-score (high) | 9.17 | 2.01 | 41.89 | .004 | .002 |
| Age | 0.98 | 0.94 | 1.02 | .29 | |||
| Sex (female) | 2.23 | 0.59 | 8.41 | .24 | |||
| wp-score + LDH | wp-score (high) | 10.85 | 2.24 | 52.64 | .003 | .001 | |
| LDH (elevated) | 5.99 | 1.47 | 24.49 | .01 | |||
| Age | 0.96 | 0.92 | 1.00 | .05 | |||
| Sex (female) | 1.23 | 0.29 | 5.12 | .78 | |||
| wp-score + IPI | wp-score (high) | 14.28 | 1.54 | 132.84 | .02 | <.001 | |
| IPI (high) | 23.44 | 3.12 | 175.87 | .002 | |||
| Age | 0.94 | 0.88 | 1.01 | .09 | |||
| Sex (female) | 11.13 | 0.97 | 128.17 | .05 | |||
| wp-score + GCB vs ABC | wp-score (high) | 20.08 | 1.37 | 293.60 | .03 | .02 | |
| Cell of origin | 4.47 | 0.78 | 25.73 | .09 | |||
| Age | 0.93 | 0.86 | 1.00 | .05 | |||
| Sex (female) | 4.27 | 0.50 | 36.92 | .19 | |||
| wp-score + stage | wp-score (high) | 6.55 | 1.28 | 33.46 | .02 | .03 | |
| Stage (advanced) | 3.99 | 0.83 | 19.24 | .08 | |||
| Age | 0.98 | 0.93 | 1.04 | .52 | |||
| Sex (female) | 2.37 | 0.50 | 11.26 | .28 |
| Outcome . | Model . | Variable . | Hazard ratio . | 95% CI (lower) . | 95% CI (upper) . | P . | Log-rank P . |
|---|---|---|---|---|---|---|---|
| OS | wp-score | wp-score (high)* | Infinite | 0.000 | Infinite | ND | .001 |
| Age | 0.98 | 0.29 | 1.02 | .29 | |||
| Sex (female) | 2.49 | 0.26 | 12.29 | .26 | |||
| EFS | wp-score | wp-score (high) | 9.17 | 2.01 | 41.89 | .004 | .002 |
| Age | 0.98 | 0.94 | 1.02 | .29 | |||
| Sex (female) | 2.23 | 0.59 | 8.41 | .24 | |||
| wp-score + LDH | wp-score (high) | 10.85 | 2.24 | 52.64 | .003 | .001 | |
| LDH (elevated) | 5.99 | 1.47 | 24.49 | .01 | |||
| Age | 0.96 | 0.92 | 1.00 | .05 | |||
| Sex (female) | 1.23 | 0.29 | 5.12 | .78 | |||
| wp-score + IPI | wp-score (high) | 14.28 | 1.54 | 132.84 | .02 | <.001 | |
| IPI (high) | 23.44 | 3.12 | 175.87 | .002 | |||
| Age | 0.94 | 0.88 | 1.01 | .09 | |||
| Sex (female) | 11.13 | 0.97 | 128.17 | .05 | |||
| wp-score + GCB vs ABC | wp-score (high) | 20.08 | 1.37 | 293.60 | .03 | .02 | |
| Cell of origin | 4.47 | 0.78 | 25.73 | .09 | |||
| Age | 0.93 | 0.86 | 1.00 | .05 | |||
| Sex (female) | 4.27 | 0.50 | 36.92 | .19 | |||
| wp-score + stage | wp-score (high) | 6.55 | 1.28 | 33.46 | .02 | .03 | |
| Stage (advanced) | 3.99 | 0.83 | 19.24 | .08 | |||
| Age | 0.98 | 0.93 | 1.04 | .52 | |||
| Sex (female) | 2.37 | 0.50 | 11.26 | .28 |
ND, not defined.
All patients in the high wp-score group are alive at the end of the follow-up period. Thus, the β estimate is infinite for OS analysis.